Hoffmann-La Roche initiates study on Satralizumab for Duchenne Muscular Dystrophy
Hoffmann-La Roche is conducting a study to evaluate the efficacy and safety of satralizumab in patients with DMD aged 8 to <18 years receiving corticosteroids.
Asset / Drug
Drug and asset intelligence for Satralizumab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.